Jefferies analyst Peter Welford says the first headline from Novo Nordisk’s (NVO) Phase III CagriSema obesity data “disappoint” with 20.4% absolute weight loss and patient adherence likely suggesting tolerability concerns. The firm’s buy-side survey suggested most anticipated 25%-27% absolute weight loss with fastrointestinal tolerability to be broadly similar to Wegovy. Jefferies notes its $7.75B peak CagriSema sales are well below the $20B-plus consensus. It expects the Novo shares to be down “at least” 10%-15% on the CagriSema obesity data. Jefferies keeps an Underperform rating on Novo Nordisk with an $81.50 price target The stock in premarket trading is down 19%, or $19.84, to $83.60.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVO:
- Novo Nordisk: Cagrisema shows ‘superior’ weight loss in REDEFINE 1 trial
- Novo Nordisk shares drop 27% premarket after releasing Cagrisema data
- Novo Nordisk says patients on Cagrisema lost 22.7% of weight in trial
- Novo Nordisk: Cagrisema weight loss showed superiority over semaglutide
- Novo Nordisk to further explore weight loss potential of Cagrisema